(Fighting New Coronary Pneumonia) Deputy Director of the National Health Commission: China has 21 new coronavirus vaccines in clinical trials

　　China News Service, Beijing, June 7. Zeng Yixin, deputy director of the National Health Commission of China and head of the vaccine research and development team of the Joint Prevention and Control Mechanism of the State Council, said in an interview with Chinese state media recently that 21 new crown vaccines in China have entered clinical trials. Experimental phase.

　　Zeng Yixin said that China currently has 4 vaccines approved for domestic market with conditions, 3 vaccines have been approved for emergency use in China, 8 vaccines have been approved for phase III clinical trials abroad, and 1 mRNA vaccine has been ethically approved abroad. It has achieved comprehensive coverage of the technical routes of inactivated vaccines, recombinant protein vaccines, adenovirus vector vaccines, and nucleic acid vaccines for overseas clinical trials.

　　In terms of international vaccine cooperation, Zeng Yixin said that China's new crown vaccine has been approved for marketing or emergency use in more than 90 countries and regions around the world, and 2 vaccines have been approved to be included in the WHO's emergency use list.

　　He pointed out that China's new crown vaccine has supplied more than 350 million doses abroad, including donations to more than 80 countries and exports to more than 40 countries.

In October 2020, China announced its participation in the New Coronary Vaccine Implementation Plan (COVAX) and promised to supply 10 million doses of vaccine.

On May 7, 2021, after the inactivated vaccine of Sinopharm Beijing Institute was included in the WHO emergency use list, on June 1, the first batch of COVAX vaccines supplied by the institute went offline.

　　Zeng Yixin also said that China is actively carrying out international cooperation in the development, production, and use of the new crown vaccine.

In terms of research and development, some vaccine research and development units have cooperated with relevant institutions in more than 20 countries, including the UAE, Brazil, Uzbekistan, the Philippines, and Pakistan, to carry out phase III clinical trials.

In terms of production, the raw liquid produced by some companies has been shipped to Brazil, Indonesia, Egypt, UAE, Pakistan, Malaysia and other countries, and overseas sub-packaging has been started.

　　As the overseas epidemic situation is still severe, it is not easy to accurately count the real-world protection rate of vaccines, but Zeng Yixin said that there are two cases that can be introduced.

　　One is that the Chilean Ministry of Health has announced that as of May 16, the country has received approximately 13.25 million doses of Kexing inactivated vaccine.

The results of the study showed that 14 days after the second dose of vaccination, the effective rate of preventing symptomatic infection was 65.3%, the effective rate of preventing hospitalization was 87%, and the effective rate of preventing entry into the intensive care unit was 90.3%, preventing death from infection The effective rate is 86%.

Taking into account the prevalence of local variants, it suggests that the Chinese vaccine may have a good cross-protection effect on the variants.

　　The second is that on June 1, Kexing released the preliminary results of the "S plan" for the new crown vaccine trial in Serana, Brazil.

Among the more than 40,000 people in the city, more than 90% of adults have completed the vaccination.

The results show that although the epidemic situation in the surrounding areas is still severe, the number of deaths due to the new crown virus in Serana has dropped by 95%, the number of symptomatic cases has dropped by 80%, and the number of hospitalizations has dropped by 86%.

In addition, vaccination also protects the immune barrier for children and adolescents who have not been vaccinated.

　　Zeng Yixin also pointed out that the large-scale domestic vaccination in China fully demonstrates the good safety of Chinese vaccines.

According to statistics, over 700 million doses of vaccination in China, the incidence of adverse reactions reported was 11.86/100,000 doses.

Among them, the general reaction accounted for 83%, and the abnormal reaction accounted for 17%. The incidence of general reaction and abnormal reaction was lower than the average reported level of various vaccines routinely vaccinated in China in 2019.

　　He also revealed that it is expected that at least 70% of the target population will be vaccinated in China by the end of this year.

(Finish)